2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3192

Influence of Temperature and Humidity on Disease Activity in Rheumatoid Arthritis
Abstract Number: 111

Influences of Osteoarthritis Pain, Comorbid Insomnia, and Depression on Health Care Use in Older Adults with Osteoarthritis
Abstract Number: 608

Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Abstract Number: 2311

Initial Predictors of Short-Term Poor Survival Rates in Patients with Polymyositis/Dermatomyositis-Associated Interstitial Lung Disease
Abstract Number: 376

Initial Validation of the Patient Reported Outcomes Measurement Information System Pediatric Pain Intensity Scale in Juvenile Idiopathic Arthritis, Juvenile Fibromyalgia and Sickle Cell Disease
Abstract Number: 2396

Initiation of Dialysis in Pediatric ANCA-Associated Vasculitis
Abstract Number: 2245

Injectable Corticosteroid Use in Musculoskeletal Care Specialties
Abstract Number: 2377

Innovative Use of PK and PD to Guide Dose Selection for a Monoclonal Antibody Aimed at Neutralizing the High IFNγ Activity Present in Patients with Macrophage Activation Syndrome (MAS)
Abstract Number: 1189

Inpatient Trends for Adults with Scleroderma in the United States: A 20 Year Analysis
Abstract Number: 77

Integrated Analysis of Microrna and mRNA Expression Profiles Related to Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Patients
Abstract Number: 3216

Integrated High-Dimensional Analyses Reveal a Pathologically Expanded ‘Peripheral’ B Cell-Helper T Cell Population in Rheumatoid Arthritis
Abstract Number: 207

Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Abstract Number: 2518

Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time
Abstract Number: 109

Inter-Professional Satisfaction and Perceptions of Collaborative Practice of an Innovative Model of Care for the Early Detection of Axial Spondyloarthritis
Abstract Number: 3198

Inter-Reader and Intra-Reader Reliability of the New Omeract Ultrasonographic Criteria for the Diagnosis of Calcium Pyrophosphate Deposition Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].